- Home
- IBO vs IMRN Comparison
IBO vs IMRN Comparison
Compare IBO & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- IMRN
- Stock Information
- Founded
- IBO 2018
- IMRN 1994
- Country
- IBO United States
- IMRN Australia
- Employees
- IBO N/A
- IMRN N/A
- Industry
- IBO
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- IMRN Health Care
- Exchange
- IBO NYSE
- IMRN Nasdaq
- Market Cap
- IBO 16.5M
- IMRN 15.0M
- IPO Year
- IBO 2024
- IMRN N/A
- Fundamental
- Price
- IBO $2.60
- IMRN $1.90
- Analyst Decision
- IBO
- IMRN Strong Buy
- Analyst Count
- IBO 0
- IMRN 1
- Target Price
- IBO N/A
- IMRN $5.00
- AVG Volume (30 Days)
- IBO 64.6K
- IMRN 6.1K
- Earning Date
- IBO 11-12-2024
- IMRN 11-26-2024
- Dividend Yield
- IBO N/A
- IMRN N/A
- EPS Growth
- IBO N/A
- IMRN N/A
- EPS
- IBO 0.02
- IMRN N/A
- Revenue
- IBO N/A
- IMRN $3,271,194.00
- Revenue This Year
- IBO N/A
- IMRN N/A
- Revenue Next Year
- IBO N/A
- IMRN N/A
- P/E Ratio
- IBO $118.52
- IMRN N/A
- Revenue Growth
- IBO N/A
- IMRN 171.67
- 52 Week Low
- IBO $1.22
- IMRN $1.59
- 52 Week High
- IBO $3.20
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- IMRN 42.61
- Support Level
- IBO N/A
- IMRN $1.73
- Resistance Level
- IBO N/A
- IMRN $1.99
- Average True Range (ATR)
- IBO 0.00
- IMRN 0.11
- MACD
- IBO 0.00
- IMRN 0.02
- Stochastic Oscillator
- IBO 0.00
- IMRN 52.25
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.